| Exploration of potential inhibitors for SARS‐CoV‐2 Mpro considering its mutants via structure‐based drug design, molecular docking, MD simulations, MM/PBSA, and DFT calculations A Ghasemlou, V Uskoković, Y Sefidbakht Biotechnology and Applied Biochemistry 70 (1), 439-457, 2023 | 7 | 2023 |
| The main protease of SARS COV-2 and its specific inhibitors A Ghassemlou, Y Sefidbakht, M Rahmandoust COVID-19: Science to Social Impact, 121-147, 2021 | 4 | 2021 |
| AI-driven covalent drug design strategies targeting main protease (mpro) against SARS-CoV-2: structural insights and molecular mechanisms MH Haghir Ebrahim Abadi, A Ghasemlou, F Bayani, Y Sefidbakht, ... Journal of Biomolecular Structure and Dynamics, 1-29, 2024 | | 2024 |
| New Coronavirus 2019 (nCoV-2019): Origin and Pathogenicity Mechanism Y Sefidbakht, A Ghasemlou, S Rezaei Science Cultivation 10 (2), 130-137, 2020 | | 2020 |
| New Coronavirus 2019 (nCoV-2019): Origin and Pathogenicity Mechanism S Rezaei, A Ghasemlou, Y SEFIDBAKHT | | 2020 |
